Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imiquimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 known ✓ | Q9NYK1 | 15/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imiquimod SCHEMBL570774 | 1.00 | TLR7 (1.00) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL29357252 | 1.00 | TLR7 (1.00) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL17962753 | 0.99 | TLR7 (0.97) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL1301796 | 0.99 | TLR7 (0.97) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL29029396 | 0.96 | TLR7 (0.93) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL5262205 | 0.94 | TLR7 (0.88) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL3191041 | 0.93 | TLR7 (0.86) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL3415170 | 0.92 | TLR7 (0.84) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL5260618 | 0.91 | TLR7 (0.82) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL9602834 | 0.91 | TLR7 (0.82) | TLR7PDE4DADORA2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 62191 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3993771-B1 | SONODYNAMIC THERAPY | INNOVATION ULSTER LTD (GB) | 2026-05-27 | — | — | EP | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122031668-A | Formulations for neoplasia vaccines | 博德研究所 | 2026-05-15 | — | — | CN | claimed |
| CN-122031401-A | MOF-based drug delivery agent for multi-mechanism synergistic tumor treatment and preparation method thereof | 理工清科(重庆)先进材料研究院有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | claimed |
| US-12622956-B2 | Methods and vaccines for inducing immune responses to multiple different MHC molecules | Mayo Foundation for Medical Education and Research; (MN) | 2026-05-12 | — | — | US | claimed |
| CN-122005785-A | Method for identifying HIV patients susceptible to therapy with GP 120V 3 glycan-directed antibodies | 吉利德科学公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260116950-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2026-04-30 | — | — | US | claimed |
| US-5238944-A | Viricides comprising isotearic acid; skin disorders | RIKER LABORATORIES, INC. (US) | 1993-08-24 | — | — | US | claimed |
| EP-0553202-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[4,5-C]QUINOLIN-4-AMINES. | MINNESOTA MINING & MFG (US) | 1993-08-04 | — | — | EP | claimed |
| US-5175296-A | Reacting 1H-imidazolo(4,5-c)quinolin-5N-oxide with organic isocyanate; hydrolysis | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-12-29 | — | — | US | claimed |
| WO-1992015581-A1 | PROCESS FOR IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-09-17 | — | — | WO | claimed |
| WO-1992006093-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[4,5-C]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-04-16 | — | — | WO | claimed |
| EP-0394026-A1 | Formulation containing an imidazo[4,5-c]quinolin derivative | RIKER LABORATORIES, INC. (US) | 1990-10-24 | — | — | EP | claimed |
| EP-0376534-A1 | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine | RIKER LABORATORIES, INC. (US) | 1990-07-04 | — | — | EP | claimed |
| EP-0145340-B1 | 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines | RIKER LABORATORIES, INC. (US) | 1990-01-24 | — | — | EP | claimed |
| US-4689338-A | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use | RIKER LABORATORIES, INC. (US) | 1987-08-25 | — | — | US | claimed |
| EP-0145340-A2 | 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines | RIKER LABORATORIES, INC. (US) | 1985-06-19 | — | — | EP | claimed |